Service providers

AdaptVac

Solution provided
Technological/Validation solutions
Supplier indentity
General description
AdaptVac’s core business is the development of vaccines for infectious diseases and cancer. AdaptVac combines a highly competitive recombinant antigen production platform with a unique virus-like particle (VLP) vaccine platform. This proprietary technology is the first achieving true VLP display of large and complex antigens. The overall strength of this technology platform is the ability to develop, with a minimal effort and alteration, any recombinant vaccine candidate into a VLP particle.
Type of supplier
Biotechnology Company - Therapeutics, Lab/scientific services platform
Sector of activity:
Activity description
Services provided
AdaptVac's VLP display technology can be used in collaboration with SMEs to improve their sub-unit vaccines against infectious diseases and cancer. We can support formulation development and production and VLP display of their vaccine antigens. Furthermore, AdaptVac has access to animal facilities to test potential vaccines and adjuvants in combination with our VLP technology.
Terms of availability for SMEs
No
Quality labels and accreditations
No
Contact information
Name
Wian de Jongh
Function
CEO
Phone number
004526394649
Email address
Address
Agern alle 1
2970 horsholm
Denmark

Upcoming events

02
Dec

With the medical devices market estimated to be worth £10+ billion (UK) in 2021, there is enough support for UK medtech companies to prosper. During the webinar, the National Institute of Health Research Office for Clinical Research Infrastructure - NOCRI, Innovate UK, Kent Surrey Sussex AHSN, EEN, KTN and DIT will outline how companies can navigate the medtech landscape of support that is available to British and European innovative medtech companies.

Agenda

Mo Tu We Th Fr Sa Su
 
 
 
 
 
 
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
 
21
 
22
 
23
 
24
 
25
 
26
 
27
 
28
 
29
 
30